Researchers Use the Simulations Plus DILIsym Platform to Predict Safety of Combined CBD and VPA Treatment
15.08.2023 - Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today shared an article published in the July 2023 issue of Clinical Pharmacology & Therapeutics in ... Seite 1
Source: wallstreet-online.de